E) many mentions in negative reviews that the negative reviews are based upon fact that movement starts at same time it did for older BONTs. Positive reviews note same thing, but then note that return to baseline takes substantially longer than with earlier BONTs. (Comment: this effect is surprising but it shows up multiple times so probably real and it would explain a lot of people’s disappointment if they are judging by movement. What fraction of practices use this measure instead of return to baseline?)
I think this is one of the biggest issues. Injectors were not properly trained by sales reps on how to set expectations for patients. Injectors hear the buzz words "6 month average duration" and this is what they were relaying to their patients. And then patients expected to get 6 months. When 4 months pass, and the patient sees movement, their first thought is the product is not working as advertised, and they call their injector to complain. Who wouldn't when the price was so high. Rather than resetting expectations, injectors have been saying, ok, c'mon in and well switch you back to Botox. Daxi meanwhile, is becoming an afterthought in these injectors minds, hence the reason many of them still aren't aware of the change in pricing. Whether Revance can reign in this problem, well, we'll have to wait and see.
Market Data 
Markets 
AI
